Multiplex Assay Kit for Hypoxia Inducible Factor 2 Alpha (HIF2a) ,etc. by FLIA (Flow Luminescence Immunoassay)

EPAS1; HLF; MOP2; PASD2; BHLHE73; Endothelial PAS Domain 1; HIF-1 Alpha-Like Factor; Basic-helix-loop-helix-PAS protein MOP2; Class E basic helix-loop-helix protein 73

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Hypoxia Inducible Factor 2 Alpha (HIF2a) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Hypoxia Inducible Factor 2 Alpha (HIF2a) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Hypoxia Inducible Factor 2 Alpha (HIF2a) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Hypoxia Inducible Factor 2 Alpha (HIF2a) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 94-103 99
EDTA plasma(n=5) 93-101 96
heparin plasma(n=5) 80-98 86
sodium citrate plasma(n=5) 81-98 92

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Hypoxia Inducible Factor 2 Alpha (HIF2a) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Hypoxia Inducible Factor 2 Alpha (HIF2a) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Hypoxia Inducible Factor 2 Alpha (HIF2a) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 79-90% 85-102% 89-97% 91-99%
EDTA plasma(n=5) 96-103% 93-101% 92-101% 88-97%
heparin plasma(n=5) 90-97% 90-104% 78-96% 86-96%
sodium citrate plasma(n=5) 92-99% 87-97% 88-95% 91-98%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:HIF2a) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Neuro Oncol Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling PubMed: 26409567
Clinical Trials in Degenerative Diseases Correlating oxidative stress-related factors with bone metabolic markers in older adult male patients exhibiting degenerative osteoporosis in the high-altitude hypoxic area of China: study protocol for a non-randomized controlled trial issn:2542-3975
Journal of Physiological Anthropology Telomere elongation protects heart and lung tissue cells from fatal damage in rats exposed to severe hypoxia Pubmed:29454386
Oxidative damage and iron dyshomeostasis in thalassemic patients
Neuropsychiatric Disease and Treatment The Association Between Hypoxia Improvement and Electroconvulsive Therapy for Major Depressive Disorder 34588778
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
RPD466Mu02 Recombinant Hypoxia Inducible Factor 2 Alpha (HIF2a) Positive Control; Immunogen; SDS-PAGE; WB.
RPD466Mu01 Recombinant Hypoxia Inducible Factor 2 Alpha (HIF2a) Positive Control; Immunogen; SDS-PAGE; WB.
PAD466Mu01 Polyclonal Antibody to Hypoxia Inducible Factor 2 Alpha (HIF2a) WB; IHC; ICC; IP.
PAD466Mu02 Polyclonal Antibody to Hypoxia Inducible Factor 2 Alpha (HIF2a) WB; IHC; ICC; IP.
LAD466Mu71 Biotin-Linked Polyclonal Antibody to Hypoxia Inducible Factor 2 Alpha (HIF2a) WB; IHC; ICC.
SED466Mu ELISA Kit for Hypoxia Inducible Factor 2 Alpha (HIF2a) Enzyme-linked immunosorbent assay for Antigen Detection.
LMD466Mu Multiplex Assay Kit for Hypoxia Inducible Factor 2 Alpha (HIF2a) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.